| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hepatitis E virus | 19 | 2019 | 306 | 6.71 | Why? |
| Hepatitis E | 15 | 2019 | 319 | 4.78 | Why? |
| Norovirus | 6 | 2019 | 294 | 2.81 | Why? |
| Rotavirus | 6 | 2019 | 329 | 1.70 | Why? |
| Rotavirus Infections | 6 | 2019 | 355 | 1.56 | Why? |
| Mycophenolic Acid | 4 | 2019 | 383 | 1.54 | Why? |
| Interferon Regulatory Factor-1 | 4 | 2019 | 33 | 1.33 | Why? |
| Liver Neoplasms | 7 | 2019 | 1666 | 1.26 | Why? |
| DEAD Box Protein 58 | 2 | 2018 | 250 | 1.17 | Why? |
| Hepatitis C, Chronic | 4 | 2019 | 973 | 1.14 | Why? |
| Caliciviridae Infections | 5 | 2019 | 229 | 1.11 | Why? |
| Protein Biosynthesis | 2 | 2019 | 653 | 1.09 | Why? |
| Carcinoma, Hepatocellular | 6 | 2019 | 1222 | 1.07 | Why? |
| Virus Replication | 13 | 2019 | 14331 | 1.05 | Why? |
| Ribavirin | 7 | 2019 | 1182 | 1.00 | Why? |
| Interferons | 5 | 2019 | 2885 | 0.95 | Why? |
| Organoids | 5 | 2019 | 840 | 0.93 | Why? |
| Viral Hepatitis Vaccines | 2 | 2018 | 58 | 0.91 | Why? |
| Hepatocytes | 4 | 2017 | 549 | 0.90 | Why? |
| STAT1 Transcription Factor | 3 | 2018 | 313 | 0.89 | Why? |
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 2 | 2018 | 19 | 0.88 | Why? |
| Hepacivirus | 4 | 2019 | 1509 | 0.88 | Why? |
| STAT2 Transcription Factor | 2 | 2018 | 141 | 0.80 | Why? |
| Hepatitis Viruses | 1 | 2019 | 38 | 0.79 | Why? |
| Antiviral Agents | 21 | 2021 | 41703 | 0.79 | Why? |
| Genotype | 9 | 2019 | 4697 | 0.78 | Why? |
| RNA, Transfer | 1 | 2019 | 66 | 0.78 | Why? |
| Hepatitis Virus, Duck | 1 | 2018 | 1 | 0.77 | Why? |
| Guanosine Diphosphate | 1 | 2018 | 3 | 0.77 | Why? |
| Drug Screening Assays, Antitumor | 1 | 2019 | 138 | 0.77 | Why? |
| Thioguanine | 1 | 2018 | 10 | 0.76 | Why? |
| Gastroenteritis | 3 | 2019 | 489 | 0.75 | Why? |
| Guanosine Triphosphate | 1 | 2018 | 29 | 0.75 | Why? |
| Directed Molecular Evolution | 1 | 2018 | 81 | 0.75 | Why? |
| rac1 GTP-Binding Protein | 1 | 2018 | 32 | 0.74 | Why? |
| Liver | 6 | 2018 | 4007 | 0.74 | Why? |
| IMP Dehydrogenase | 1 | 2017 | 13 | 0.73 | Why? |
| Gene Silencing | 2 | 2019 | 213 | 0.72 | Why? |
| Gentamicins | 1 | 2018 | 76 | 0.72 | Why? |
| TOR Serine-Threonine Kinases | 2 | 2019 | 385 | 0.71 | Why? |
| Cholestasis | 1 | 2019 | 114 | 0.71 | Why? |
| Biliary Tract Diseases | 1 | 2018 | 60 | 0.70 | Why? |
| Liver Regeneration | 1 | 2017 | 38 | 0.70 | Why? |
| Interferon-Stimulated Gene Factor 3 | 1 | 2017 | 22 | 0.69 | Why? |
| Rabbits | 2 | 2018 | 1171 | 0.69 | Why? |
| Protein Kinase C-alpha | 1 | 2017 | 12 | 0.68 | Why? |
| Chlamydia trachomatis | 1 | 2019 | 172 | 0.68 | Why? |
| Papillomaviridae | 2 | 2019 | 404 | 0.67 | Why? |
| Cholangitis | 1 | 2018 | 81 | 0.67 | Why? |
| Signal Transduction | 12 | 2019 | 7207 | 0.67 | Why? |
| Interferon-alpha | 4 | 2018 | 1442 | 0.66 | Why? |
| Thiazoles | 2 | 2018 | 496 | 0.64 | Why? |
| Hepatitis, Viral, Human | 1 | 2019 | 196 | 0.64 | Why? |
| Interferon-Induced Helicase, IFIH1 | 1 | 2018 | 245 | 0.63 | Why? |
| Calcineurin Inhibitors | 1 | 2017 | 218 | 0.63 | Why? |
| Cytoplasm | 1 | 2017 | 304 | 0.61 | Why? |
| Chlamydia Infections | 1 | 2019 | 248 | 0.61 | Why? |
| Neonatal Screening | 1 | 2019 | 285 | 0.61 | Why? |
| Streptococcal Infections | 1 | 2019 | 255 | 0.60 | Why? |
| Sofosbuvir | 2 | 2019 | 518 | 0.59 | Why? |
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 347 | 0.57 | Why? |
| Disease Models, Animal | 5 | 2019 | 10998 | 0.56 | Why? |
| Phosphorylation | 5 | 2018 | 1060 | 0.56 | Why? |
| Interferon Regulatory Factor-3 | 1 | 2017 | 379 | 0.55 | Why? |
| Cellular Senescence | 1 | 2017 | 326 | 0.53 | Why? |
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 502 | 0.51 | Why? |
| Intestinal Mucosa | 2 | 2018 | 1046 | 0.50 | Why? |
| Papillomavirus Infections | 2 | 2019 | 861 | 0.50 | Why? |
| Liver Transplantation | 2 | 2019 | 2864 | 0.50 | Why? |
| Cell Line, Tumor | 6 | 2019 | 3608 | 0.49 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 451 | 0.48 | Why? |
| Mitochondria | 1 | 2019 | 857 | 0.47 | Why? |
| Stents | 1 | 2019 | 916 | 0.46 | Why? |
| Neoplasm Recurrence, Local | 1 | 2019 | 1063 | 0.45 | Why? |
| Cell Proliferation | 3 | 2019 | 1973 | 0.45 | Why? |
| Stem Cells | 1 | 2017 | 595 | 0.44 | Why? |
| Caco-2 Cells | 4 | 2019 | 1236 | 0.44 | Why? |
| Interferon-gamma | 2 | 2018 | 2711 | 0.44 | Why? |
| Gene Expression Regulation | 4 | 2019 | 4020 | 0.43 | Why? |
| Autophagy | 2 | 2019 | 960 | 0.43 | Why? |
| RNA Viruses | 1 | 2018 | 824 | 0.43 | Why? |
| Neurons | 1 | 2017 | 864 | 0.42 | Why? |
| Transcription, Genetic | 1 | 2017 | 1326 | 0.42 | Why? |
| Postoperative Complications | 2 | 2019 | 5861 | 0.42 | Why? |
| Cells, Cultured | 6 | 2018 | 5835 | 0.40 | Why? |
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 907 | 0.38 | Why? |
| Hepatitis, Chronic | 2 | 2019 | 53 | 0.38 | Why? |
| Mice | 10 | 2019 | 21357 | 0.38 | Why? |
| Disease Susceptibility | 2 | 2019 | 4002 | 0.37 | Why? |
| Hepatitis C | 2 | 2017 | 1514 | 0.37 | Why? |
| Constriction, Pathologic | 2 | 2019 | 212 | 0.35 | Why? |
| Bile Ducts | 2 | 2018 | 84 | 0.35 | Why? |
| Primary Cell Culture | 2 | 2019 | 501 | 0.34 | Why? |
| Intestines | 3 | 2018 | 817 | 0.34 | Why? |
| Immunity, Innate | 4 | 2019 | 6570 | 0.34 | Why? |
| Evolution, Molecular | 2 | 2019 | 3691 | 0.33 | Why? |
| Nitro Compounds | 2 | 2018 | 190 | 0.33 | Why? |
| Protein Kinase Inhibitors | 1 | 2017 | 1585 | 0.32 | Why? |
| Host-Pathogen Interactions | 5 | 2019 | 11041 | 0.32 | Why? |
| Phosphoproteins | 1 | 2017 | 4346 | 0.32 | Why? |
| Health Resources | 1 | 2020 | 2592 | 0.31 | Why? |
| Animals | 16 | 2019 | 78931 | 0.31 | Why? |
| Replicon | 2 | 2018 | 232 | 0.31 | Why? |
| Immunity | 1 | 2017 | 2651 | 0.29 | Why? |
| Immunity, Cellular | 1 | 2018 | 3614 | 0.28 | Why? |
| Janus Kinases | 2 | 2018 | 414 | 0.27 | Why? |
| Immunosuppressive Agents | 3 | 2019 | 6331 | 0.27 | Why? |
| Receptors, Immunologic | 2 | 2018 | 555 | 0.26 | Why? |
| Humans | 57 | 2021 | 930598 | 0.25 | Why? |
| Liver Diseases | 1 | 2018 | 2698 | 0.24 | Why? |
| Viral Proteins | 2 | 2018 | 7370 | 0.24 | Why? |
| Mutation, Missense | 2 | 2018 | 863 | 0.23 | Why? |
| Kidney Transplantation | 2 | 2019 | 5397 | 0.23 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2019 | 5164 | 0.23 | Why? |
| Coronavirus | 2 | 2021 | 18339 | 0.22 | Why? |
| Epigenesis, Genetic | 2 | 2018 | 711 | 0.22 | Why? |
| Cervix Uteri | 2 | 2019 | 146 | 0.21 | Why? |
| Respiratory Tract Infections | 1 | 2021 | 6817 | 0.21 | Why? |
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2019 | 15 | 0.20 | Why? |
| Eukaryotic Initiation Factor-4F | 1 | 2019 | 1 | 0.20 | Why? |
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2019 | 1 | 0.20 | Why? |
| Genetic Code | 1 | 2019 | 16 | 0.20 | Why? |
| Mitochondrial Dynamics | 1 | 2019 | 30 | 0.20 | Why? |
| Gene Knockdown Techniques | 2 | 2019 | 347 | 0.20 | Why? |
| Uterine Cervical Diseases | 1 | 2019 | 4 | 0.20 | Why? |
| Brain | 1 | 2017 | 5133 | 0.20 | Why? |
| Anti-Bacterial Agents | 2 | 2019 | 10083 | 0.20 | Why? |
| Thioridazine | 1 | 2018 | 5 | 0.19 | Why? |
| Peste-des-Petits-Ruminants | 1 | 2018 | 5 | 0.19 | Why? |
| Peste-des-petits-ruminants virus | 1 | 2018 | 6 | 0.19 | Why? |
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2018 | 2 | 0.19 | Why? |
| Genome, Viral | 2 | 2018 | 13157 | 0.19 | Why? |
| Interferon Regulatory Factor-7 | 1 | 2019 | 234 | 0.18 | Why? |
| Coinfection | 1 | 2019 | 6820 | 0.18 | Why? |
| Far East | 1 | 2018 | 125 | 0.18 | Why? |
| Calcineurin | 1 | 2017 | 38 | 0.18 | Why? |
| Odds Ratio | 3 | 2019 | 5861 | 0.18 | Why? |
| Xenograft Model Antitumor Assays | 1 | 2019 | 274 | 0.18 | Why? |
| Drug Synergism | 2 | 2018 | 833 | 0.18 | Why? |
| Amino Acid Transport System y+ | 1 | 2017 | 6 | 0.18 | Why? |
| Diphtheria Toxin | 1 | 2017 | 9 | 0.18 | Why? |
| Recurrence | 2 | 2019 | 3675 | 0.18 | Why? |
| Tacrolimus Binding Protein 1A | 1 | 2017 | 29 | 0.18 | Why? |
| Stem Cell Niche | 1 | 2017 | 16 | 0.18 | Why? |
| Carbon Tetrachloride | 1 | 2017 | 27 | 0.18 | Why? |
| Chick Embryo | 1 | 2018 | 249 | 0.18 | Why? |
| Bile Ducts, Intrahepatic | 1 | 2018 | 68 | 0.18 | Why? |
| Streptococcus agalactiae | 1 | 2019 | 194 | 0.17 | Why? |
| Codon | 1 | 2019 | 287 | 0.17 | Why? |
| Antineoplastic Agents | 3 | 2019 | 3550 | 0.17 | Why? |
| Tetradecanoylphorbol Acetate | 1 | 2017 | 23 | 0.17 | Why? |
| Mutation | 2 | 2017 | 12376 | 0.17 | Why? |
| Ribosomes | 1 | 2019 | 200 | 0.17 | Why? |
| Transduction, Genetic | 1 | 2018 | 273 | 0.17 | Why? |
| gamma-Glutamyltransferase | 1 | 2017 | 101 | 0.17 | Why? |
| Erythrocyte Indices | 1 | 2018 | 207 | 0.17 | Why? |
| DNA, Viral | 2 | 2019 | 2521 | 0.17 | Why? |
| Embryo, Mammalian | 1 | 2017 | 86 | 0.16 | Why? |
| Transcription Factor AP-1 | 1 | 2017 | 75 | 0.16 | Why? |
| Indonesia | 2 | 2019 | 1022 | 0.16 | Why? |
| Sustained Virologic Response | 1 | 2019 | 378 | 0.16 | Why? |
| Gene Expression Regulation, Developmental | 1 | 2017 | 159 | 0.16 | Why? |
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 130 | 0.16 | Why? |
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2017 | 98 | 0.16 | Why? |
| Models, Genetic | 1 | 2019 | 434 | 0.16 | Why? |
| Lentivirus | 1 | 2018 | 310 | 0.16 | Why? |
| DNA Replication | 1 | 2017 | 121 | 0.16 | Why? |
| Antigenic Variation | 1 | 2017 | 249 | 0.16 | Why? |
| Wnt Signaling Pathway | 1 | 2016 | 87 | 0.16 | Why? |
| Michigan | 1 | 2020 | 988 | 0.16 | Why? |
| Antigen-Antibody Complex | 1 | 2018 | 408 | 0.16 | Why? |
| RNA, Viral | 4 | 2018 | 32276 | 0.16 | Why? |
| Cell Lineage | 1 | 2017 | 241 | 0.16 | Why? |
| RNA, Untranslated | 1 | 2017 | 140 | 0.15 | Why? |
| Sirolimus | 1 | 2018 | 240 | 0.15 | Why? |
| Antibiotic Prophylaxis | 1 | 2019 | 399 | 0.15 | Why? |
| Transcriptional Activation | 1 | 2017 | 196 | 0.15 | Why? |
| Green Fluorescent Proteins | 1 | 2017 | 450 | 0.15 | Why? |
| Conserved Sequence | 1 | 2018 | 751 | 0.15 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.15 | Why? |
| Drug Therapy, Combination | 3 | 2019 | 7268 | 0.15 | Why? |
| Enzyme Activation | 1 | 2017 | 425 | 0.15 | Why? |
| Cerebrospinal Fluid | 1 | 2017 | 234 | 0.15 | Why? |
| Cytidine | 1 | 2017 | 219 | 0.15 | Why? |
| Cell Line | 4 | 2018 | 12040 | 0.15 | Why? |
| Cell Cycle Proteins | 1 | 2017 | 297 | 0.14 | Why? |
| Liver Failure, Acute | 1 | 2018 | 279 | 0.14 | Why? |
| Vasodilator Agents | 1 | 2018 | 344 | 0.14 | Why? |
| Agammaglobulinemia | 1 | 2017 | 213 | 0.14 | Why? |
| Genetic Diseases, X-Linked | 1 | 2017 | 237 | 0.14 | Why? |
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 372 | 0.14 | Why? |
| Tacrolimus | 1 | 2017 | 435 | 0.14 | Why? |
| Protein Stability | 1 | 2017 | 756 | 0.14 | Why? |
| Adaptation, Physiological | 1 | 2017 | 359 | 0.14 | Why? |
| NF-kappa B | 2 | 2018 | 1301 | 0.13 | Why? |
| Colitis | 1 | 2017 | 266 | 0.13 | Why? |
| Receptors, G-Protein-Coupled | 1 | 2017 | 309 | 0.13 | Why? |
| HEK293 Cells | 2 | 2018 | 8394 | 0.13 | Why? |
| Immunotherapy | 2 | 2017 | 2421 | 0.13 | Why? |
| China | 7 | 2021 | 50654 | 0.13 | Why? |
| Cyclosporine | 1 | 2017 | 449 | 0.13 | Why? |
| RNA, Small Interfering | 1 | 2018 | 817 | 0.13 | Why? |
| Promoter Regions, Genetic | 1 | 2017 | 823 | 0.13 | Why? |
| Fatty Liver | 1 | 2017 | 299 | 0.13 | Why? |
| Polymerase Chain Reaction | 2 | 2019 | 6740 | 0.13 | Why? |
| Pregnancy Complications, Infectious | 1 | 2019 | 11559 | 0.12 | Why? |
| Secondary Prevention | 1 | 2018 | 762 | 0.12 | Why? |
| Fibroblasts | 1 | 2017 | 839 | 0.12 | Why? |
| Vaccines, Attenuated | 1 | 2018 | 952 | 0.12 | Why? |
| Lipid Metabolism | 1 | 2017 | 572 | 0.12 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2017 | 724 | 0.12 | Why? |
| Pyridones | 1 | 2018 | 738 | 0.12 | Why? |
| Kaplan-Meier Estimate | 2 | 2019 | 4260 | 0.12 | Why? |
| Up-Regulation | 2 | 2017 | 2249 | 0.12 | Why? |
| Cell Culture Techniques | 1 | 2017 | 704 | 0.12 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.12 | Why? |
| Virus Activation | 1 | 2017 | 480 | 0.12 | Why? |
| DNA Methylation | 1 | 2017 | 688 | 0.12 | Why? |
| Phenotype | 3 | 2018 | 4037 | 0.12 | Why? |
| Orthomyxoviridae | 1 | 2020 | 1168 | 0.12 | Why? |
| Interferon-beta | 1 | 2018 | 979 | 0.12 | Why? |
| Mice, Knockout | 1 | 2017 | 1815 | 0.11 | Why? |
| Antigens, CD | 1 | 2017 | 984 | 0.11 | Why? |
| Databases, Genetic | 1 | 2017 | 1127 | 0.11 | Why? |
| Gene Expression Regulation, Viral | 1 | 2017 | 925 | 0.11 | Why? |
| Cell Differentiation | 1 | 2017 | 1338 | 0.11 | Why? |
| Virulence | 1 | 2018 | 2172 | 0.11 | Why? |
| Genetic Vectors | 1 | 2018 | 1600 | 0.11 | Why? |
| Alanine Transaminase | 1 | 2017 | 1329 | 0.11 | Why? |
| Crystallography, X-Ray | 1 | 2018 | 2689 | 0.11 | Why? |
| Population Surveillance | 2 | 2018 | 4967 | 0.11 | Why? |
| Aspartate Aminotransferases | 1 | 2017 | 1394 | 0.10 | Why? |
| Mice, Transgenic | 1 | 2017 | 2739 | 0.10 | Why? |
| Viral Tropism | 1 | 2018 | 1329 | 0.10 | Why? |
| Mycobacterium tuberculosis | 1 | 2019 | 1164 | 0.10 | Why? |
| Hepatitis B virus | 1 | 2017 | 882 | 0.10 | Why? |
| Sequence Analysis, DNA | 1 | 2018 | 2830 | 0.10 | Why? |
| Peptides | 1 | 2021 | 2513 | 0.09 | Why? |
| Young Adult | 5 | 2020 | 93724 | 0.09 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.09 | Why? |
| Hepatitis B | 1 | 2017 | 888 | 0.09 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.09 | Why? |
| Mothers | 1 | 2019 | 1624 | 0.09 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.09 | Why? |
| Endoscopy | 1 | 2019 | 1564 | 0.09 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.09 | Why? |
| Risk Factors | 6 | 2019 | 71621 | 0.09 | Why? |
| Infant | 3 | 2020 | 30274 | 0.09 | Why? |
| Models, Molecular | 2 | 2021 | 7616 | 0.09 | Why? |
| RNA, Messenger | 2 | 2019 | 5131 | 0.09 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2018 | 2483 | 0.09 | Why? |
| Adult | 11 | 2020 | 244371 | 0.09 | Why? |
| Needs Assessment | 1 | 2018 | 2352 | 0.08 | Why? |
| Premature Birth | 1 | 2019 | 2151 | 0.08 | Why? |
| Middle Aged | 11 | 2020 | 270681 | 0.08 | Why? |
| Dose-Response Relationship, Drug | 1 | 2016 | 3776 | 0.08 | Why? |
| Carrier State | 1 | 2019 | 2100 | 0.08 | Why? |
| Female | 13 | 2020 | 380317 | 0.08 | Why? |
| Macaca mulatta | 1 | 2017 | 3716 | 0.08 | Why? |
| Child, Preschool | 3 | 2020 | 36283 | 0.08 | Why? |
| Amino Acid Sequence | 1 | 2018 | 6049 | 0.08 | Why? |
| Incidence | 2 | 2019 | 25622 | 0.08 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.08 | Why? |
| Mice, Inbred BALB C | 1 | 2017 | 5814 | 0.08 | Why? |
| Drug Evaluation, Preclinical | 1 | 2018 | 3347 | 0.08 | Why? |
| Proteomics | 1 | 2017 | 2481 | 0.08 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.08 | Why? |
| Adaptive Immunity | 1 | 2017 | 2585 | 0.08 | Why? |
| Epithelial Cells | 1 | 2018 | 3508 | 0.08 | Why? |
| Viruses | 1 | 2019 | 2238 | 0.07 | Why? |
| MicroRNAs | 1 | 2018 | 1787 | 0.07 | Why? |
| Treatment Outcome | 4 | 2019 | 51732 | 0.07 | Why? |
| Protein Domains | 1 | 2018 | 6563 | 0.07 | Why? |
| Cohort Studies | 2 | 2019 | 36005 | 0.07 | Why? |
| Aged | 8 | 2020 | 215776 | 0.07 | Why? |
| Epitopes | 1 | 2017 | 4113 | 0.07 | Why? |
| Interferon Type I | 1 | 2018 | 2789 | 0.07 | Why? |
| Stress Disorders, Post-Traumatic | 1 | 2021 | 2963 | 0.07 | Why? |
| Prospective Studies | 2 | 2020 | 43301 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.07 | Why? |
| Guillain-Barre Syndrome | 1 | 2017 | 1495 | 0.07 | Why? |
| Kidney | 1 | 2018 | 3648 | 0.07 | Why? |
| Bacterial Infections | 1 | 2017 | 2229 | 0.06 | Why? |
| Male | 12 | 2020 | 367725 | 0.06 | Why? |
| Tuberculosis | 1 | 2019 | 2895 | 0.06 | Why? |
| Phylogeny | 2 | 2019 | 13341 | 0.06 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.06 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.06 | Why? |
| Transplant Recipients | 1 | 2019 | 4982 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| Developing Countries | 1 | 2018 | 4283 | 0.06 | Why? |
| HIV Infections | 2 | 2018 | 11620 | 0.06 | Why? |
| Child | 3 | 2021 | 70012 | 0.06 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.05 | Why? |
| Aged, 80 and over | 3 | 2020 | 88759 | 0.05 | Why? |
| Virus Shedding | 1 | 2017 | 5834 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2019 | 10649 | 0.05 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.05 | Why? |
| T-Lymphocytes | 1 | 2017 | 6670 | 0.05 | Why? |
| Sequence Analysis, RNA | 2 | 2019 | 2290 | 0.05 | Why? |
| Prevalence | 2 | 2019 | 25773 | 0.05 | Why? |
| Substrate Specificity | 1 | 2021 | 639 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2018 | 6153 | 0.05 | Why? |
| Guanosine | 1 | 2018 | 29 | 0.05 | Why? |
| Inflammation | 2 | 2019 | 13255 | 0.05 | Why? |
| NF-KappaB Inhibitor alpha | 1 | 2018 | 63 | 0.05 | Why? |
| Health Status Disparities | 1 | 2017 | 4072 | 0.05 | Why? |
| Cytokines | 2 | 2018 | 15010 | 0.05 | Why? |
| Amino Acid Transport System y+L | 1 | 2017 | 1 | 0.05 | Why? |
| I-kappa B Kinase | 1 | 2018 | 98 | 0.04 | Why? |
| Phosphoglycerate Dehydrogenase | 1 | 2017 | 4 | 0.04 | Why? |
| Amino Acid Transport System ASC | 1 | 2017 | 6 | 0.04 | Why? |
| Tumor Escape | 1 | 2017 | 36 | 0.04 | Why? |
| Bacterial Physiological Phenomena | 1 | 2017 | 31 | 0.04 | Why? |
| Apoptosis Regulatory Proteins | 1 | 2019 | 202 | 0.04 | Why? |
| Antibodies, Monoclonal | 1 | 2017 | 8041 | 0.04 | Why? |
| Hep G2 Cells | 1 | 2019 | 391 | 0.04 | Why? |
| RAW 264.7 Cells | 1 | 2018 | 316 | 0.04 | Why? |
| Infant, Newborn | 1 | 2019 | 23105 | 0.04 | Why? |
| Hepatitis Antibodies | 1 | 2018 | 100 | 0.04 | Why? |
| Minor Histocompatibility Antigens | 1 | 2017 | 56 | 0.04 | Why? |
| Human papillomavirus 16 | 1 | 2017 | 95 | 0.04 | Why? |
| Ipilimumab | 1 | 2017 | 102 | 0.04 | Why? |
| Armed Conflicts | 1 | 2020 | 209 | 0.04 | Why? |
| Coculture Techniques | 1 | 2017 | 258 | 0.04 | Why? |
| SEER Program | 1 | 2017 | 146 | 0.04 | Why? |
| Urbanization | 1 | 2017 | 133 | 0.04 | Why? |
| beta Catenin | 1 | 2016 | 78 | 0.04 | Why? |
| Religion | 1 | 2020 | 353 | 0.04 | Why? |
| Cervical Intraepithelial Neoplasia | 1 | 2017 | 114 | 0.04 | Why? |
| Pregnancy | 1 | 2019 | 23879 | 0.04 | Why? |
| Depression | 1 | 2021 | 14116 | 0.04 | Why? |
| Genotyping Techniques | 1 | 2019 | 360 | 0.04 | Why? |
| CpG Islands | 1 | 2017 | 230 | 0.04 | Why? |
| Molecular Structure | 1 | 2021 | 1539 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.04 | Why? |
| CTLA-4 Antigen | 1 | 2017 | 282 | 0.04 | Why? |
| Cell Transformation, Neoplastic | 1 | 2016 | 191 | 0.04 | Why? |
| Tumor Microenvironment | 1 | 2017 | 264 | 0.04 | Why? |
| Middle East | 1 | 2020 | 1418 | 0.04 | Why? |
| Genetic Engineering | 1 | 2017 | 325 | 0.04 | Why? |
| Surveys and Questionnaires | 2 | 2021 | 43792 | 0.04 | Why? |
| Mendelian Randomization Analysis | 1 | 2017 | 317 | 0.03 | Why? |
| Transfection | 1 | 2017 | 864 | 0.03 | Why? |
| Mental Health | 1 | 2021 | 15770 | 0.03 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.03 | Why? |
| RNA Interference | 1 | 2017 | 534 | 0.03 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2019 | 1136 | 0.03 | Why? |
| Viral Structural Proteins | 1 | 2016 | 491 | 0.03 | Why? |
| Infliximab | 1 | 2017 | 502 | 0.03 | Why? |
| Fecal Microbiota Transplantation | 1 | 2017 | 372 | 0.03 | Why? |
| Sexual Partners | 1 | 2017 | 612 | 0.03 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.03 | Why? |
| Cooperative Behavior | 1 | 2020 | 1216 | 0.03 | Why? |
| Nitric Oxide | 1 | 2019 | 769 | 0.03 | Why? |
| Neoplasm Proteins | 1 | 2017 | 501 | 0.03 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 952 | 0.03 | Why? |
| RNA-Binding Proteins | 1 | 2019 | 1022 | 0.03 | Why? |
| Protective Factors | 1 | 2017 | 1720 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Neoplasms | 1 | 2019 | 17251 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2017 | 25288 | 0.03 | Why? |
| Retrospective Studies | 2 | 2019 | 105322 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2017 | 1648 | 0.02 | Why? |
| Prognosis | 3 | 2018 | 32490 | 0.02 | Why? |
| Neoplasm Staging | 1 | 2017 | 1999 | 0.02 | Why? |
| Dendritic Cells | 1 | 2018 | 1330 | 0.02 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.02 | Why? |
| Drug Design | 1 | 2021 | 2627 | 0.02 | Why? |
| Uterine Cervical Neoplasms | 1 | 2017 | 842 | 0.02 | Why? |
| Binding Sites | 1 | 2021 | 6201 | 0.02 | Why? |
| Molecular Dynamics Simulation | 1 | 2021 | 4155 | 0.02 | Why? |
| Netherlands | 1 | 2017 | 3533 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2017 | 2742 | 0.02 | Why? |
| Macrophages | 1 | 2019 | 2784 | 0.02 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1573 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2018 | 4758 | 0.02 | Why? |
| Monocytes | 1 | 2019 | 2978 | 0.02 | Why? |
| Computer Simulation | 1 | 2021 | 4982 | 0.02 | Why? |
| Molecular Docking Simulation | 1 | 2021 | 6902 | 0.02 | Why? |
| Feces | 1 | 2019 | 4235 | 0.02 | Why? |
| Liver Cirrhosis | 1 | 2016 | 1810 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Protein Binding | 1 | 2021 | 11430 | 0.02 | Why? |
| Biomarkers | 2 | 2017 | 23361 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2017 | 3129 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.01 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.01 | Why? |
| Communication | 1 | 2020 | 5206 | 0.01 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.01 | Why? |
| Seroepidemiologic Studies | 1 | 2018 | 10017 | 0.01 | Why? |
| Vero Cells | 1 | 2018 | 14117 | 0.01 | Why? |
| Mortality | 1 | 2017 | 7132 | 0.01 | Why? |
| Immunoglobulin M | 1 | 2018 | 9091 | 0.01 | Why? |
| Drug Repositioning | 1 | 2018 | 5683 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 11367 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2018 | 21571 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.01 | Why? |